

pHet-Act1-1

Catalog No(s). 635061 (Not sold separately). Sold as part of 635065.

Amount 20 μl pHet-Act1-1Vector (500 ng/μl) **Lot Number** Specified on product label.

pHet-Act1-1 Vector Information




Figure 1. pHet-Act1-1 vector map.

Clontech Laboratories, Inc.

A Takara Bio Company

1290 Terra Bella Avenue, Mountain View, CA 94043, USA

Asia Pacific

U.S. Technical Support: tech@clontech.com

800.662.2566 Late update: July 12, 2011

United States/Canada

Location of Features

- P_{CMV} (human cytomegalovirus promoter): 19–613
- 5' UTR (HSV TK 5' untranslated region): 615–653
- NLS (nuclear localization signal): 682–708
- DmrC (dimerization domain C): 709–993
- p65 AD (NF-kB p65 activation domain, aa 361–551): 1000–1581
- IRES (encephalomyocarditis virus internal ribosome entry site): 1590–2093
- NLS (nuclear localization signal): 2105–2131
- ZFHD1 DBD (ZFHD1 DNA binding domain): 2138–2500
- DmrA (dimerization domain A): 2504–2827; 2834–3154; & 3158–3481
- 3' UTR (rabbit beta-globin 3' untranslated region, includes polyA signal): 3500–4661
- P_{SV40} (SV40 promoter): 4670–4865 (complementary)
- SV40 origin of replication: 4748–4825 (complementary)
- pUC origin of replication: 5087–5706 (complementary)
- Amp^r (ampicillin resistance gene; β-lactamase): 5861–6733 (complementary)
- f1 origin of replication: 7302–7608 (complementary)

NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

Last update: July 12, 2011 Page 2 of 2